Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5)

A Corrigendum to this article was published on 04 July 2006


Erectile dysfunction (ED) is frequent in patients with essential hypertension (EH); a likely common pathogenetic pathway could be a reduced ability of arteriolar vascular smooth muscle (VSM) to relax. Increasing intracellular levels of cGMP reduce the contractile status of VSM; on the contrary, type 5 cGMP-specific phosphodiesterase (PDE5, codified by PDE5A gene) regulates cGMP levels through its clearance. The PDE5A gene represents a good candidate for the intermediate phenotype EH/ED: genetic variants of the PDE5A may predispose to EH and ED and could affect the local and systemic response to sildenafil administration. Thus, a functionally relevant portion of PDE5 5′-flanking promoter region was analyzed by PCR and direct sequencing in patients with EH and idiopathic ED. The sequences obtained showed a T/G polymorphism at position –1142, near an AP1 regulatory element, that was not apparently associated with the intermediate phenotype. We also studied the relationship between this polymorphism and the effects of oral sildenafil on blood pressure (BP) and heart rate (HR) in men with ED. Sildenafil caused a significant decrease of BP, but had no effects on HR; statistical analysis showed no differences in BP and HR variations among PDE5A genotypes. In conclusion, our data showed no correlations of a novel polymorphism of the PDE5A promoter gene with the intermediate phenotype EH/ED and the BP and HR response to sildenafil administration. Further studies are necessary to define the role of this polymorphism and to study the genetic predisposition for EH with ED.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3


  1. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

  2. Martin-Morales A et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569–574.

    CAS  Google Scholar 

  3. Derby CA, Barbour MM, Hume AL, McKinlay JB . Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001; 21: 676–683.

    Article  CAS  Google Scholar 

  4. Karadeniz T et al. Correlation of ultrastructural alterations in cavernous tissue with the clinical diagnosis vasculogenic hypertension. Urol Int 1996; 57: 58–61.

    Article  CAS  Google Scholar 

  5. Burchardt M et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 1188–1191.

    Article  CAS  Google Scholar 

  6. McVary KT, Carrier S, Wessels H . Smoking and erectile dysfunction: evidence based analysis. J Urol 2001; 166: 1624–1632.

    Article  CAS  Google Scholar 

  7. Fedele D et al. Incidence of erectile dysfunction in Italian men with diabetes. J Urol 2001; 166: 1368–1371.

    Article  CAS  Google Scholar 

  8. Jaffe A et al. Erectile dysfunction in hypertensive subjects. Assessment of potential determinants. Hypertension 1996; 28: 859–862.

    Article  CAS  Google Scholar 

  9. Wespes E . Smooth muscle pathology and erectile dysfunction. Int J Impot Res 2002; 14(Suppl): S17–21.

    Article  Google Scholar 

  10. Panza JA . Endothelial dysfunction in essential hypertension. Clin Cardiol 1997; 20: 26–33.

    Article  Google Scholar 

  11. Murad F . Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986; 78: 1–5.

    Article  CAS  Google Scholar 

  12. Garbers DL, Dubois SK . The molecular basis of hypertension. Annu Rev Biochem 1999; 68: 127–155.

    Article  CAS  Google Scholar 

  13. Saenz De Tejada I . Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2002; 14(Suppl): S6–S10.

    Article  Google Scholar 

  14. Lue TF . Erectile dysfunction. N Engl J Med 2000; 342: 1802–1813.

    Article  CAS  Google Scholar 

  15. Boolell M et al. An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52.

    CAS  Google Scholar 

  16. Morales A et al. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–74.

    Article  CAS  Google Scholar 

  17. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med 1998; 338: 1397–1404.

    Article  CAS  Google Scholar 

  18. Herrmann HC, Chang G, Klugherz BD, Mahoney PD . Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622–1626.

    Article  CAS  Google Scholar 

  19. Summary of death reports in Viagra received from marketing (late March) through June 1998. Food and Drug Administration (Center for Drug Evaluation and Research): Washington, DC, 1998.

  20. Inoue I et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99: 1786–1797.

    Article  CAS  Google Scholar 

  21. Kupari M et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998; 97: 569–575.

    Article  CAS  Google Scholar 

  22. Sarzani R et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower ANP and higher blood pressure in obese hypertensives. J Hypertens 1999; 17: 1301–1305.

    Article  CAS  Google Scholar 

  23. Yanaka N et al. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 1998; 255: 391–399.

    Article  CAS  Google Scholar 

  24. Pilz RB et al. Nitric oxide and cGMP analogs activate transcription from AP-1-responsive promoters in mammalian cells. FASEB J 1995; 9: 552–558.

    Article  CAS  Google Scholar 

  25. Pawliczak R et al. p11 expression in human bronchial epithelial cells is increased by nitric oxide in a cGMP-dependent pathway involving protein kinase G activation. J Biol Chem 2001; 276: 44613–44621.

    Article  CAS  Google Scholar 

  26. Lin CS, Lau A, Tu R, Lue TF . Identification of three alternative first exons and an intronic promoter of human PDE5A gene. Biochem Biophys Res Commun 2000; 268: 628–635.

    Article  CAS  Google Scholar 

  27. Lin CS et al. Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun 2001; 280: 684–692.

    Article  CAS  Google Scholar 

  28. Lin CS et al. Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. Biochem Biophys Res Commun 2001; 280: 693–699.

    Article  CAS  Google Scholar 

  29. Lin CS et al. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 2002; 14: 15–24.

    Article  Google Scholar 

  30. Zusman RM, Prisant ML, Brown MJ, for the Sildenafil Study Group. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J Hypertens 2000; 18: 1865–1869.

    Article  CAS  Google Scholar 

  31. Arruda-Olson AM et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 14: 719–725.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to F Salvi.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Salvi, F., Sarzani, R., Giorgi, R. et al. Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5). Int J Impot Res 16, 412–417 (2004).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • erectile dysfunction
  • sildenafil
  • PDE5 alleles
  • hypertension

This article is cited by


Quick links